|
Delayed
London S.E.
03:59:59 2026-10-27 EDT
|
5-day change | 1st Jan Change | ||
| 0.1750 GBX | 0.00% |
|
-2.78% | -12.50% |
| 10-19 | Cora Gold shareholder Eagle Eye restructures holding | AN |
| 10-19 | TheraCryf Completes Preclinical Safety Studies for Orexin-1 Addiction Drug Candidate | MT |
Projected Income Statement: Theracryf Plc
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.5487 | 0.5059 | - | - | - | - |
| Change | - | - | -7.81% | - | - | - | - |
| EBITDA | -3.996 | -6.32 | -4.54 | -2.574 | -4.535 | - | - |
| Change | - | -58.17% | 28.16% | 43.3% | -76.18% | - | - |
| EBIT 1 | -4.016 | -6.336 | -4.555 | -2.878 | -4.892 | -3.6 | -3.6 |
| Change | - | -57.78% | 28.11% | 36.82% | -69.98% | 26.41% | 0% |
| Interest Paid | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -3.986 | -6.214 | -4.555 | -2.825 | -4.724 | -3.56 | -3.56 |
| Change | - | -55.92% | 26.7% | 37.98% | -67.21% | 24.64% | 0% |
| Net income 1 | -3.433 | -5.019 | -4.007 | -2.63 | -4.675 | -2.955 | -2.955 |
| Change | - | -46.18% | 20.16% | 34.37% | -77.75% | 36.79% | 0% |
| Announcement Date | 6/8/22 | 6/7/23 | 5/28/24 | 6/3/25 | 9/28/26 | - | - |
1USD in Million
Estimates
Forecast Balance Sheet: Theracryf Plc
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | -11.3 | -6.23 | -2.56 | -2.85 | -0.62 | -0.07 | 3.02 |
| Change | - | 44.87% | 58.91% | -11.33% | 78.25% | 88.78% | 4,414.29% |
| Announcement Date | 6/8/22 | 6/7/23 | 5/28/24 | 6/3/25 | 9/28/26 | - | - |
1USD in Million
Estimates
Cash Flow Forecast: Theracryf Plc
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| CAPEX 1 | - | - | - | - | - | 0.00265 | 0.00265 |
| Change | - | - | - | - | - | - | 0% |
| Free Cash Flow (FCF) 1 | -3.915 | -5.142 | -3.828 | -3.2 | -3.515 | - | - |
| Change | - | -31.35% | 25.55% | 16.42% | -9.86% | 100% | - |
| Announcement Date | 6/8/22 | 6/7/23 | 5/28/24 | 6/3/25 | 9/28/26 | - | - |
1USD in Million
Estimates
Forecast Financial Ratios: Theracryf Plc
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | - | - | -1,151.82% | -897.47% | - | - | - | - |
| EBIT Margin (%) | - | - | -1,154.76% | -900.5% | - | - | - | - |
| EBT Margin (%) | - | - | -1,132.59% | -900.5% | - | - | - | - |
| Net margin (%) | - | - | -914.71% | -792.17% | - | - | - | - |
| FCF margin (%) | - | - | -937.2% | -756.79% | - | - | - | - |
| FCF / Net Income (%) | - | 114.02% | 102.46% | 95.53% | 121.66% | 75.19% | - | - |
Profitability | ||||||||
| ROA | -23.25% | -18.1% | -40.35% | -48.26% | -24.83% | -37.12% | - | - |
| ROE | -33.39% | -25.95% | -55.51% | -81.67% | -46.71% | -81.3% | - | - |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Debt / Free cash flow | - | - | - | - | - | - | - | - |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | - | - | - | - | - | - | - | - |
| CAPEX / EBITDA (%) | - | - | - | - | - | - | - | - |
| CAPEX / FCF (%) | - | - | - | - | - | - | - | - |
Items per share | ||||||||
| Cash flow per share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Dividend per Share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Book Value Per Share 1 | - | 0.0421 | 0.0242 | 0.0115 | 0.015 | 0.00172 | - | - |
| Change | - | - | -42.62% | -52.42% | 30.35% | -88.53% | - | - |
| EPS 1 | - | -0.0124 | -0.0182 | -0.0146 | -0.00488 | -0.00212 | -0.00119 | -0.00106 |
| Change | - | - | -46.59% | 20.22% | 66.48% | 56.56% | 43.87% | 10.92% |
| Nbr of stocks (in thousands) | - | 274,888 | 274,888 | 354,288 | 2,129,622 | 2,148,964 | 2,732,297 | 2,732,297 |
| Announcement Date | - | 6/8/22 | 6/7/23 | 5/28/24 | 6/3/25 | 9/28/26 | - | - |
1USD
Estimates
| 2027 * | 2028 * | |
|---|---|---|
| P/E | -1.96x | -2.2x |
| PBR | - | - |
| EV / Sales | - | - |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.002336USD
Average target price
0.0159USD
Spread / Average Target
+580.14%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- EVG Stock
- Financials Theracryf Plc
Select your edition
All financial news and data tailored to specific country editions
